Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. - Bergmann, L.; Albiges, L.; Ahrens, M.; Gross-Goupil, M.; Boleti, E.; Gravis, G.; Fléchon, A.; Grimm, M.-O.; Bedke, J.; Barthélémy, P.; Castellano, D.; Mellado, B.; et al. (Annals of Oncology, 2025)